Prospective neoadjuvant analysis of PET imaging and mechanisms of resistance to Trastuzumab shows role of HIF1 and autophagy

Por Koukourakis, M I, Giatromanolaki, A, Bottini, A, Cappelletti, M R, Zanotti, L, Allevi, G, Strina, C, Ardine, M, Milani, M, Brugnoli, G, Martinotti, M, Ferrero, G, Bertoni, R, Ferrozzi, F, Harris, A L, Generali, D
Publicado em 2014

Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

Por Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D
Publicado em 2013

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

Por Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D
Publicado no Br J Cancer (2015)